Drugs to Watch report: 15 blockbusters for 2023

Clarivate study highlights treatments with blockbuster potential | IV, Parkinson’s disease, Crohn’s disease, alopecia, multiple myeloma and breast cancer make the list | Nine blockbusters from China also predicted.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

J&J unit win shuts door on Sandoz generic launch

10 September 2026 Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.

Pharma

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

7 September 2026 A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.

Pharma

Teva faces scrutiny over efforts to curb generic competition

27 August 2026 Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.

More features

Built to be bought? What makes companies acquisition-ready

Patent lawyers and judges discuss lofty UPC issues in grand London venue

J&J names two-decade veteran as chief IP counsel

J&J unit win shuts door on Sandoz generic launch

Abbott clinches 18-country PI in glucose monitoring feud

UK firm hires head of IP with commercial and technical nous

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

G 1/25: EPO settles controversial patent description question

Drugs to Watch report: 15 blockbusters for 2023

More on this story

Editor's picks

Editor's picks

More features